These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10189270)

  • 21. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data.
    Wyska E; Mager DE; Krzyzanski W
    J Pharm Sci; 2003 Jul; 92(7):1438-54. PubMed ID: 12820148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.
    Gabrielsson J; Hjorth S; Vogg B; Harlfinger S; Gutierrez PM; Peletier L; Pehrson R; Davidsson P
    Eur J Pharm Sci; 2015 Jan; 67():144-159. PubMed ID: 25435491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat.
    Mandema JW; Wada DR
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1185-94. PubMed ID: 8531080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.
    Louizos C; Yáñez JA; Forrest ML; Davies NM
    J Pharm Pharm Sci; 2014; 17(1):34-91. PubMed ID: 24735761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of baseline parameters in determining indirect pharmacodynamic responses.
    Sun YN; Jusko WJ
    J Pharm Sci; 1999 Oct; 88(10):987-90. PubMed ID: 10514344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The maximum pharmacodynamic effect as a response parameter: pharmacokinetic considerations.
    Leopold CS
    J Pharm Pharmacol; 1999 Sep; 51(9):999-1008. PubMed ID: 10528981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats.
    Ekblom M; Hammarlund-Udenaes M; Paalzow L
    J Pharmacol Exp Ther; 1993 Jul; 266(1):244-52. PubMed ID: 8331561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.
    Sharma A; Jusko WJ
    Br J Clin Pharmacol; 1998 Mar; 45(3):229-39. PubMed ID: 9517366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maxsim2 - Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics.
    Gabrielsson J; Andersson K; Tobin G; Ingvast-Larsson C; Jirstrand M
    Comput Methods Programs Biomed; 2014 Mar; 113(3):815-29. PubMed ID: 24461798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A theory of drug tolerance and dependence I: a conceptual analysis.
    Peper A
    J Theor Biol; 2004 Aug; 229(4):477-90. PubMed ID: 15246785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic model for educational simulations.
    van Meurs WL; Nikkelen E; Good ML
    IEEE Trans Biomed Eng; 1998 May; 45(5):582-90. PubMed ID: 9581056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application.
    Minto CF; Schnider TW; Shafer SL
    Anesthesiology; 1997 Jan; 86(1):24-33. PubMed ID: 9009936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2001 Feb; 28(1):57-78. PubMed ID: 11253614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of four basic models of indirect pharmacodynamic responses.
    Dayneka NL; Garg V; Jusko WJ
    J Pharmacokinet Biopharm; 1993 Aug; 21(4):457-78. PubMed ID: 8133465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.
    McClellan KJ; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):311-24. PubMed ID: 27521015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
    Fetterly GJ; Owen JS; Stuyckens K; Passarell JA; Zannikos P; Soto-Matos A; Izquierdo MA; Perez-Ruixo JJ
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):135-47. PubMed ID: 17922277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodological issues in pharmacokinetic-pharmacodynamic modelling.
    Bellissant E; Sébille V; Paintaud G
    Clin Pharmacokinet; 1998 Aug; 35(2):151-66. PubMed ID: 9739481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerance to the hypnotic and electroencephalographic effect of gamma-hydroxybutyrate in the rat: pharmacokinetic and pharmacodynamic aspects.
    Van Sassenbroeck DK; De Paepe P; Belpaire FM; Boon PA; Buylaert WA
    J Pharm Pharmacol; 2003 May; 55(5):609-15. PubMed ID: 12831503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.